Early-stage no longer means what it used to. In 2026, tougher early rounds, shifting capital allocation and different speeds of innovation are reshaping the investment landscape. How are investors redefining “early-stage” across MedTech, diagnostics and digital health? What does this evolution mean for capital access, valuation and development strategies? This session will explore how the sector is adapting and what founders must anticipate to stay aligned with investor expectations.
What is “early stage” in 2026? Investors on the evolution of the sector and the impact on capital
Moderated roundtable discussion consisting in an exchange of ideas and perspectives by international experts to delve into the latest challenges of the sector.
- 10:15 AM
- 11:00 AM
Moderated roundtable discussion consisting in an exchange of ideas and perspectives by international experts to delve into the latest challenges of the sector.
Panel discussion
- Dominik Leisi, Investment Manager, Atlantic Bridge Capital
- Arezki Yaïche, Head of Coverage France, Mergermarket (ION Group)
- Constant Beroulle, Associate, Newfund